# Citations for Research Query

**Query:** # Mechanistic Hypothesis Search

You are evaluating a specific disease mechanism hypothesis for the Disorder
Mechanisms Knowledge Base. This is not a general disease overview. Use the
hypothesis YAML below as the seed claim, then search for evidence that supports,
refutes, qualifies, or competes with this hypothesis.

## Target Disease
- **Disease Name:** Deregulated Nutrient Sensing Module
- **Category:** Module

## Target Hypothesis
- **Hypothesis ID:** ovarian_mtor_follicle_reserve_aging
- **Hypothesis Label:** mTOR Signaling Drives Human Ovarian Aging Through Follicle Reserve Depletion
- **Status in KB:** EMERGING

## Seed Hypothesis YAML

```yaml
hypothesis_group_id: ovarian_mtor_follicle_reserve_aging
hypothesis_label: mTOR Signaling Drives Human Ovarian Aging Through Follicle Reserve Depletion
status: EMERGING
description: The ovary ages earlier than any other organ, and mTOR signaling is the pathway the human
  ovarian aging atlas singles out as ovary-specific. This hypothesis holds that rising mTOR signaling
  in the aging ovary accelerates activation of dormant primordial follicles and so depletes the follicle
  reserve, which sets the timing of reproductive aging and menopause. It predicts that transient mTOR
  inhibition preserves the reserve and extends ovarian lifespan. Two points are open. The human evidence
  is transcript abundance of mTOR-pathway genes in eight ovaries, not measured kinase activity, and the
  one validated gene (RICTOR) belongs to mTORC2, so it is unsettled whether mTORC1, mTORC2 or both are
  involved and in which cell types. And the inhibition evidence is from mice, where long-term rapamycin
  also impairs follicle development and ovulation, so benefit depends on dosing schedule.
evidence:
- reference: PMID:39578560
  reference_title: Molecular and genetic insights into human ovarian aging from single-nuclei multi-omics
    analyses.
  supports: SUPPORT
  directness: INDIRECT
  evidence_source: HUMAN_CLINICAL
  snippet: Our analyses reveal coordinated changes in transcriptomes and chromatin accessibilities across
    cell types in the ovary during aging, notably mTOR signaling being a prominent ovary-specific aging
    pathway.
  explanation: Human single-nucleus data from four young and four reproductively aged ovaries name mTOR
    signaling as the ovary-specific aging pathway. INDIRECT because it reports pathway gene expression,
    not that mTOR activity causes reserve loss.
- reference: PMID:28544226
  reference_title: Short-term rapamycin treatment increases ovarian lifespan in young and middle-aged
    female mice.
  supports: SUPPORT
  evidence_source: MODEL_ORGANISM
  snippet: The effects of transient rapamycin treatment on ovarian lifespan were reflected in the preservation
    of primordial follicles, increases in oocyte quality, and improvement in the ovarian microenvironment.
  explanation: Two weeks of rapamycin in young or middle-aged mice prolongs ovarian lifespan with preserved
    primordial follicles, the prediction this hypothesis makes.
- reference: PMID:31887337
  reference_title: Rapamycin treatment maintains developmental potential of oocytes in mice and follicle
    reserve in human cortical fragments grafted into immune-deficient mice.
  supports: SUPPORT
  evidence_source: MODEL_ORGANISM
  snippet: Using human ovarian cortical fragments grafted into immune-deficient mice, we demonstrated
    the ability of rapamycin to suppress follicle growth from the primordial stage.
  explanation: Extends the follicle-activation effect of mTOR inhibition to human ovarian tissue, though
    in xenografts rather than in women.
- reference: PMID:28544226
  reference_title: Short-term rapamycin treatment increases ovarian lifespan in young and middle-aged
    female mice.
  supports: REFUTE
  evidence_source: MODEL_ORGANISM
  snippet: However, the application is limited because of its detrimental effects on follicular development
    and ovulation during long-term treatment.
  explanation: 'Against a simple reading that less mTOR is better for the ovary: sustained inhibition
    harms follicle development, so the benefit is schedule-dependent.'
- reference: clinicaltrials:NCT05836025
  reference_title: Effect of Rapamycin in Ovarian Aging
  supports: SUPPORT
  directness: INDIRECT
  evidence_source: OTHER
  snippet: The investigators are proposing a prospective, randomized, double-blind, placebo-controlled
    pilot study assessing the ability of low-dose rapamycin to delay ovarian aging in women.
  explanation: A registered human trial (VIBRANT) testing the hypothesis's prediction in women. It is
    a registration, not a result, so it records that the test is under way rather than supporting the
    mechanism.
notes: Scoped to the ovary. It is separate from sex_dimorphic_geroprotector_exposure, which concerns whole-animal
  lifespan in both sexes and cannot be tested with female-only ovarian data.
```

## Research Objective

Build a focused hypothesis-search report that answers:

1. What is the strongest direct evidence for this hypothesis?
2. What evidence argues against it, fails to reproduce it, or limits its scope?
3. Which claims are established, emerging, speculative, or contradicted?
4. Which patient subtypes, stages, tissues, cell types, molecular pathways, or
   biomarkers does the hypothesis best explain?
5. Which alternative or competing mechanistic hypotheses explain the same disease
   features better or more parsimoniously?
6. What are the explicit knowledge gaps: missing causal steps, unconfirmed edges,
   contradictory evidence, unknown source-to-target links, or source/data absences?
7. What experiments, cohorts, assays, datasets, or trials would most directly
   distinguish this hypothesis from alternatives?

Use primary literature whenever possible. Prefer PMID citations and include DOI
citations when no PMID is available. Treat reviews as orientation unless they
contain directly relevant synthesized evidence that should be clearly labeled as
review-level support.

When dataset or scientific-tool access is available, use it for questions that
can be tested computationally rather than limiting the run to literature search.
Preflight the required data lake, databases, packages, credentials, and tools
before claiming that an analysis can run. Never silently fall back from a failed
dataset/tool analysis to literature synthesis or model knowledge: report the
failure, the fallback, and the resulting limitation explicitly. A proposed
analysis must never be described as performed.

## Required Output

### Executive Judgment

Give a concise verdict on the hypothesis as of the current literature:
supported, partially supported, unresolved, weakly supported, or refuted. Explain
the reasoning and the most important caveats.

### Evidence Matrix

Create a table with one row per important evidence item:

- Citation (PMID preferred)
- Evidence type (human clinical, model organism, in vitro, computational, review)
- Supports / refutes / qualifies / competing
- Mechanistic claim tested
- Key finding
- Disease subtype or context
- Confidence and limitations

### Data and Tool Use

Inventory every dataset, database, API, supplementary file, or local input
material to the report. For each, state:

- stable accession or URI, repository/source, version or snapshot, and retrieval
  date where known;
- whether it was only cited/proposed, actually accessed, searched with no usable
  result, or could not be verified;
- the exact query, filters, cohort, sample subset, organism, tissue, assay, and
  comparison used where applicable;
- whether the accession resolved and whether its subject matter is genuinely
  relevant to this disease and hypothesis.

For accessed sources and negative searches, save a sanitized query response,
input manifest, or search log in the provider artifact bundle; prose alone does
not establish access or a negative result.

Inventory each attempted analysis separately. Trace input -> method -> output,
including software/model versions, material parameters, code or workflow,
environment, random seeds where relevant, output files, and limitations. Label
the execution outcome as succeeded, partial, failed, skipped, or reported-only.
Do not count a prose assertion without inspectable execution evidence as a
successful analysis.

### Mechanistic Causal Chain

Describe the causal chain implied by the hypothesis from upstream trigger to
clinical manifestation. Identify where the literature is strong, where the links
are inferred, and where there are missing causal steps.

### Knowledge Gaps

Identify explicit known unknowns surfaced by the search. Treat absence of
evidence as a curation-relevant finding only when the search actually checked for
it. Include:

- Unknown or weakly supported causal steps in the hypothesis
- Unconfirmed causal graph edges that need direct perturbation or longitudinal
  evidence
- Conflicting evidence, failed replications, or incompatible subtype-specific
  findings
- Unknown mechanism of action for relevant treatments, biomarkers, or
  interventions tied to this hypothesis
- Source-level or dataset-level absences, such as no relevant GenCC, ClinGen,
  trial, omics, or cohort evidence found as of the search date

For each gap, state the scope, why it matters, what was checked, and what
evidence or experiment would resolve it. A negative database search must include
the database/version, query, filters, and search date; otherwise label it
unverified rather than claiming absence.

### Alternative Models

List competing or complementary hypotheses. For each, explain whether it is an
alternative to the seed hypothesis, a downstream consequence, an upstream cause,
or a parallel mechanism.

### Discriminating Tests

Recommend concrete studies or assays that would most efficiently test this
hypothesis against alternatives. Include patient stratification, biomarkers,
sample type, model system, perturbation, and expected result where applicable.

### Curation Leads

Provide candidate updates for the KB, but label these as leads requiring curator
verification. Include:

- candidate evidence references and exact abstract snippets to verify
- candidate pathophysiology nodes or edges
- candidate ontology terms for cell types and biological processes
- candidate subtype restrictions or status changes
- candidate `knowledge_gaps` or discussion prompts for unresolved causal claims,
  conflicting evidence, or explicit source/data absences

If the provider supports artifacts, produce a provider artifact bundle containing
canonical `MANIFEST.yaml` (schema version, status/fallback flags, checksummed
inputs/outputs, and replay verification), code/query/configuration, an
environment or package-version record,
sanitized execution logs, and small derived tables/figures needed to inspect the
result beneath `kb/hypotheses/deregulated_nutrient_sensing/ovarian_mtor_follicle_reserve_aging/openscientist_artifacts`. Do not create an empty bundle when no data
source was accessed and no analysis ran. Give each artifact a stable relative
path and connect computed claims to their input, method, and output artifacts.
Do not bundle large recoverable raw
downloads, a provider data lake, controlled/patient-level data, credentials, or
signed URLs; record their stable external identifiers, versions, and checksums
instead. State explicitly when an expected artifact is external, local-only,
missing, or was not produced.

**Provider:** openscientist
**Generated:** 2026-10-18T04:52:03.648498

1. PMID:23326514
2. PMID:28544226
3. PMID:31887337
4. PMID:38070496
5. PMID:39578560
6. PMID:25564616
7. PMID:26414677
8. PMID:35493704
9. PMID:42580602
10. PMID:25590233
11. PMID:23677591
12. PMID:26656301
13. PMID:24357391
14. PMID:27513022
15. PMID:27621233
16. PMID:27491879
17. PMID:42271623
18. PMID:41243550
19. PMID:42693473